openPR Logo
Press release

Proteros and Institut Pasteur Korea establish discovery services collaboration in the field of infectious diseases

05-25-2011 08:08 AM CET | Science & Education

Press release from: Proteros biostructures GmbH

Martinsried, Germany, May 24, 2011. Proteros Biostructures GmbH (Proteros) announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K. Under this collaboration Proteros will apply its know-how, experience of structural analysis and its proprietary X-ray crystallography platform to support IP-K’s mission to develop therapeutics for infectious diseases.

Cony D’Cruz, Chief Business Officer of Proteros, stated, “Institut Pasteur Korea is a world class translational research institute, renowned as a centre of excellence in biomedical research and technology development with a clear focus on infectious and neglected disease. We welcome the opportunity for Proteros to contribute to these efforts.”

Dr. Michel Liuzzi, Director, Early Discovery Program at IP-K, added "We are very pleased with the expertise and know-how of Proteros in providing timely X-ray crystallography support to our in-house drug discovery projects and we look forward to continue collaborating with Proteros in the future."

About Proteros:

Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables ‘knowledge driven lead engineering’ to accelerate and improve protein structure analysis and structure-based drug discovery. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.

About Institut Pasteur Korea:

Institut Pasteur Korea (IP-K) is an independent non-profit institute founded in April, 2004 with a strategic focus on enabling technologies and therapeutic development in disease models pertaining to public health. IP-K has developed a novel research platform that combines chemical genomics with high content visual screening by bringing together the latest advances in biology, technology, and chemistry. The application of the platform technology in the fields of infectious disease and chronic illness allows basic science to be extended to drug discovery. In turn the application of functional genomics - using global siRNA - allows further elucidation of the basic molecular and genetic underpinnings of disease. Visit http://www.ip-korea.org.

Contact:
Proteros biostructures GmbH
Kurt Herrenknecht, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 0
E-Mail: business@proteros.com
Internet: www.proteros.com

Institut Pasteur Korea
Jean Kim
Sampyeong-dong 696
Bundang-gu, Seongnam-si, Gyeonggi-do
Korea
Phone: +82 (0) 31 8018 8041
E-Mail: publicrelations@ip-korea.org
Internet: www.ip-korea.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Proteros and Institut Pasteur Korea establish discovery services collaboration in the field of infectious diseases here

News-ID: 176395 • Views: 1119

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for Korea

Bamboo Salt Market Analysis Report By Key Players- Korea Salt (Korea), HK3 Marke …
The Report published on UpMarketResearch.com about “Bamboo Salt Market” is spread across 95 pages and provides newest industry data, market future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists and studies the leading competitors, also provides the insights with strategic industry Analysis of the key factors influencing the market. Get FREE Sample Copy Of This Report @
Beer Market in South Korea
Summary This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Beer in South Korea Description The social and political environment significantly influenced sales of beer in 2016, with increasing numbers of consumers drinking alone, and the implications of the anti-bribery law. The former helped to fuel growing sales of global beer brands in convenience stores, whilst the
South Korea Biosimilar Market Analysis
South Korea has emerged as one of the strategic location for the development of biosimilars on the global level. Among the various emerging countries identified for development of biosimilars, South Korea is one of the most promising countries where pharmaceutical companies have identified huge investment potentials for the drug development process. One of the major reasons for the attractiveness of South Korea is the end of patent protection for some
Agrochemicals Market in South Korea
ReportsWorldwide has announced the addition of a new report title South Korea: Agrochemicals: Market Intelligence (2016-2021) to its growing collection of premium market research reports. The report “South Korea: Agrochemicals: Market Intelligence (2016-2021)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2016-2021) has been provided in terms of both, value (000 USD) and volume (000 KG) in the
Packaged Food in South Korea
Summary Overall packaged food continued to show positive value growth in 2016. New products were actively introduced, which affected other categories by creating a sensation. Although many popular new products tend to drop suddenly as they are rapidly replaced with the appearance of another new trend, fast-changing trends of packaged food in South Korea are what drive positive value growth in overall package food. Health and wellness packaged food also shows
Autonomous Shipping South Korea Project
Naval Defence Consulting launch the hybrid autonomous shipping solutions with remote operated vessels, vessels in convoy, what is now referred to as “Platooning” the first ship in a convoy of ships send its acceleration/retardation data to the following ships, enabling them to hold course and thereby save fuel and reduce carbon footprint. Naval Defence Consulting will work with South Korean maritime bodies to pilot this next-step nautical strategy where